SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc. (Amendment)

2/9/24 9:16:05 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $IONS alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.17 IONIS PHARMACEUTICALS INC COMMON STOCK Cusip #462222100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #462222100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 21,519,114 Item 6: 0 Item 7: 21,520,872 Item 8: 0 Item 9: 21,520,872 Item 11: 15.000% Item 12: HC Cusip #462222100 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 21,520,872 Item 8: 0 Item 9: 21,520,872 Item 11: 15.000% Item 12: IN Item 1(a). Name of Issuer: IONIS PHARMACEUTICALS INC Item 1(b). Address of Issuer's Principal Executive Offices: 2855 GAZELLE COURT Carlsbad, CA 92010 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 462222100 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 21,520,872 (b) Percent of Class: 15.000% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 21,520,872 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of IONIS PHARMACEUTICALS INC. The interest of Fidelity Growth Company Commingled Pool, in the COMMON STOCK of IONIS PHARMACEUTICALS INC, amounted to 9,268,403 shares or 6.460% of the total outstanding COMMON STOCK at December 29, 2023. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company * BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of IONIS PHARMACEUTICALS INC at December 29, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $IONS alert in real time by email

Recent Analyst Ratings for

$IONS

Date	Price Target	Rating	Analyst
7/1/2025	$57.00	Equal Weight → Overweight	Barclays
4/7/2025	$45.00	Buy	H.C. Wainwright
3/31/2025	$39.00	Neutral	Redburn Atlantic
8/2/2024	$67.00 → $60.00	Outperform → Market Perform	BMO Capital Markets
7/24/2024	$53.00 → $62.00	Market Perform → Outperform	Leerink Partners
7/16/2024	$29.00 → $75.00	Buy	Jefferies
6/14/2024	$44.00	Underperform → Mkt Perform	Bernstein
4/10/2024	$58.00	Peer Perform → Outperform	Wolfe Research

More analyst ratings

SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc. (Amendment)

2/9/24 9:16:05 AM ET

$IONS

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $IONS alert in real time by email

Recent Analyst Ratings for

$IONS

Date	Price Target	Rating	Analyst
7/1/2025	$57.00	Equal Weight → Overweight	Barclays
4/7/2025	$45.00	Buy	H.C. Wainwright
3/31/2025	$39.00	Neutral	Redburn Atlantic
8/2/2024	$67.00 → $60.00	Outperform → Market Perform	BMO Capital Markets
7/24/2024	$53.00 → $62.00	Market Perform → Outperform	Leerink Partners
7/16/2024	$29.00 → $75.00	Buy	Jefferies
6/14/2024	$44.00	Underperform → Mkt Perform	Bernstein
4/10/2024	$58.00	Peer Perform → Outperform	Wolfe Research

More analyst ratings

SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc. (Amendment)

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $IONS

SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc. (Amendment)

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $IONS

$IONS SEC Filings

Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

$IONS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Ionis Pharma upgraded by Barclays with a new price target

H.C. Wainwright initiated coverage on Ionis Pharma with a new price target

Redburn Atlantic initiated coverage on Ionis Pharma with a new price target

$IONS Press Releases

Fastest customizable press release news feed in the world

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)

Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice

Ionis to hold second quarter 2025 financial results webcast

$IONS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Loscalzo Joseph converted options into 4,079 shares, increasing direct ownership by 13% to 36,330 units (SEC Form 4)

Director Parshall B Lynne converted options into 4,079 shares, increasing direct ownership by 5% to 91,344 units (SEC Form 4)

Director Wender Joseph H converted options into 4,079 shares (SEC Form 4)

$IONS Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4)

Director Hayden Michael R bought $181,079 worth of shares (5,000 units at $36.22), increasing direct ownership by 17% to 35,219 units (SEC Form 4)

$IONS Financials

Live finance-specific insights

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

Ionis reports first quarter 2025 financial results

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results

$IONS Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

SEC Form SC 13G filed by Ionis Pharmaceuticals Inc.

$IONS Leadership Updates

Live Leadership Updates

Alltrna Announces Updates to Its Board of Directors

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

Ionis announces the appointment of Michael Yang to Board of Directors

Recent Analyst Ratings for
$IONS

Recent Analyst Ratings for
$IONS

$IONS
SEC Filings

$IONS
Analyst Ratings

$IONS
Press Releases

$IONS
Insider Trading

$IONS
Insider Purchases

$IONS
Financials

$IONS
Large Ownership Changes

$IONS
Leadership Updates